Cargando…

Letrozole in advanced breast cancer: the PO25 trial

Mostrar otras versiones (1)

Detalles Bibliográficos
Autor principal:	Mouridsen, Henning T.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer US 2007
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001226/ http://dx.doi.org/10.1007/s10549-007-9570-3

Ejemplares similares

Letrozole in advanced breast cancer: the PO25 trial
por: Mouridsen, Henning T.
Publicado: (2007)

Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

The early days of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2008)

The discovery and mechanism of action of letrozole
por: Bhatnagar, Ajay S.
Publicado: (2007)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2008)

Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome [Erratum]
Publicado: (2017)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

Letrozole in the extended adjuvant setting: MA.17
por: Goss, Paul E.
Publicado: (2008)

L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?
por: DeGregorio, Michael, et al.
Publicado: (2012)

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives, Potchavit, et al.
Publicado: (2015)

Erratum to: DL- and PO-phosphatidylcholines as a promising learning and memory enhancer
por: Nagata, Tetsu, et al.
Publicado: (2015)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
por: O’Shaughnessy, Joyce, et al.
Publicado: (2017)

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
por: Alkner, S., et al.
Publicado: (2017)

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
por: Fasching, Peter A, et al.
Publicado: (2014)

Erratum to: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

Locally Advanced Breast Cancer: Autologous Versus Implant-based Reconstruction: Erratum
Publicado: (2016)

Erratum: Role of Scintimammography in Assessing the Response of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
Publicado: (2016)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Letrozole sensitizes breast cancer cells to ionizing radiation
por: Azria, David, et al.
Publicado: (2005)

Letrozole Induced Hypercalcemia in a Patient with Breast Cancer
por: Ipekci, Suleyman Hilmi, et al.
Publicado: (2014)

Erratum: Vol. 66, No. 25
Publicado: (2017)

Erratum to: DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases
por: Budach, Wilfried, et al.
Publicado: (2015)

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
por: Kim, Jisun, et al.
Publicado: (2014)

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
por: Sonke, Gabe S., et al.
Publicado: (2017)

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
por: Darvishi, Ali, et al.
Publicado: (2023)

Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma
por: Lu, Xinli, et al.
Publicado: (2022)

Erratum: Vol. 66, No. SS-25
Publicado: (2020)

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
por: Brufsky, Adam, et al.
Publicado: (2021)

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
por: Fein, Luis, et al.
Publicado: (2023)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Erratum, Vol. 9, October 25 Release
Publicado: (2012)

Erratum, Vol. 10, April 25 Release
Publicado: (2013)

Erratum, Vol. 10, July 25 Release
Publicado: (2013)

Erratum, Vol. 13, February 25 Release
Publicado: (2016)

Erratum for Euro Surveill. 2020;25(41)
Publicado: (2020)

Erratum for Euro Surveill. 2020;25(33)
Publicado: (2020)

Erratum for Euro Surveill. 2020;25(43)
Publicado: (2020)

Erratum for Euro Surveill. 2020;25(5)
Publicado: (2020)

Erratum for Euro Surveill. 2020;25(3)
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lrm6nfvc89fr41cir34n6cra9s